共 126 条
[31]
Ludwig WD(2000)A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma Ann Oncol 11 861-61
[32]
Fülle HH(2004)Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients Br J Haematol 124 754-20
[33]
Hagenbeek A(2006)Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma Cancer 106 2412-9
[34]
Eghbali H(2004)Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies Cancer 100 2181-8
[35]
Monfardini S(1997)Results of a fludarabine induction and α-interferon maintenance protocol in pretreated patients with chronic lymphocytic leukemia and low-grade non-Hodgkin’s lymphoma Eur J Haematol 59 82-18
[36]
Klasa RJ(1997)A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma Blood 89 3909-9
[37]
Meyer RM(2005)ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of newly diagnosed large cell non-Hodgkin’s lymphoma Ann Oncol 16 i58-7
[38]
Shustik C(2005)Minimum clinical recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma Ann Oncol 16 156-1
[39]
Foussard C(2005)ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of relapsed large cell non-Hodgkin’s lymphoma Ann Oncol 16 160-8
[40]
Colombat P(2004)Predictive factors for successful stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine [letter] Leukemia 18 1034-49